Omnicell Jumps 7.8% Amid Sector-Wide Rally
Omnicell's shares surged 7.8% to $46.37 on July 6, 2026, as part of a broad sector-wide rally in health information services. The increase, driven by widespread buying interest rather than company-specific news, saw several peers also making significant gains. Investors are advised to monitor whether this momentum will be sustained.
Enterprise value to EBIT forward of Omnicell, Inc. – NASDAQ:OMCL
This article focuses on the enterprise value to EBIT forward for Omnicell, Inc. (NASDAQ: OMCL). It provides a brief financial overview of the company within the TradingView platform, indicating market closure and no recent trades. The content primarily serves as a placeholder or data point for financial analysis.
Is Omnicell (OMCL) A Bargain Following Its New President Appointment?
Omnicell (OMCL) is gaining investor attention after appointing Nnamdi Njoku as President, sparking interest in its long-term strategy. The stock price of $41.93 suggests it might be undervalued, with a narrative fair value of $61.29 driven by strong demand for its medication management solutions in healthcare. However, its high P/E ratio compared to the industry indicates that some optimism may already be priced in.
Is Omnicell (OMCL) A Bargain Following Its New President Appointment?
Omnicell (OMCL) is under investor scrutiny after appointing Nnamdi Njoku as President while he continues as COO, a move that could significantly impact its long-term strategy and product development. Despite recent positive share price momentum, the company's valuation presents a mixed picture. While Simply Wall St's narrative suggests Omnicell is 31.6% undervalued with a fair value of $61.29, driven by strong demand for its medication management solutions, its current P/E ratio of 93.3x is considerably higher than industry averages, prompting questions about whether market optimism is already baked into the price.
Is Omnicell (OMCL) A Bargain Following Its New President Appointment?
Omnicell (OMCL) recently appointed Nnamdi Njoku as President, sparking renewed interest in the stock. Trading at $41.93, analysts suggest it could be undervalued by approximately 31.6%, with a fair value around $61.29, driven by strong demand for its medication management solutions in healthcare. However, its high P/E ratio of 93.3x compared to industry averages raises questions about whether optimism is already priced in, urging investors to evaluate future earnings against current valuations.
Omnicell appoints Nnamdi Njoku as president effective today
Omnicell has appointed Nnamdi Njoku as President, effective immediately, while he retains his role as Chief Operating Officer. Randall Lipps will continue as CEO and Chairman, focusing on strategy. Njoku will oversee global operations, growth, and innovation, including the launch of the Omnicell Titan XT system, with the company showing strong financial performance and positive analyst revisions.
Omnicell, Inc. Announces Executive Changes
Omnicell, Inc. has announced significant executive changes, with Nnamdi Njoku being appointed President of the Company, effective July 1, 2026. He will retain his role as Chief Operating Officer (COO), while Randall Lipps continues as Chief Executive Officer and Chairman, focusing on strategic collaborations and product evolution. This move follows Mr. Njoku's previous role as Executive Vice President and COO and his extensive experience in medical technology leadership at companies like Zimmer Biomet and Medtronic.
Omnicell Appoints Nnamdi Njoku President, Retaining COO Role
Omnicell, Inc. has announced the appointment of Nnamdi Njoku as President, effective July 1, 2026, while he continues his role as Chief Operating Officer. CEO Randall Lipps will remain focused on strategic collaborations and the company's long-term solution portfolio. Njoku will lead Omnicell's growth strategy, innovation roadmap, and global operations, including the launch of key products like the Omnicell Titan XT and expansion of the OmniSphere platform.
Omnicell appoints Nnamdi Njoku as president effective today By Investing.com
Omnicell, Inc. has announced the appointment of Nnamdi Njoku as President, effective immediately, while he will also retain his role as Chief Operating Officer. Randall Lipps will continue as CEO and Chairman, focusing on strategic collaborations. Njoku will oversee global operations, growth strategy, and innovation, including the launch of new products and expansion of the OmniSphere platform.
Nnamdi Njoku Appointed President of Omnicell
Omnicell, Inc., a healthcare technology provider, announced the appointment of Nnamdi Njoku as President, effective July 1, 2026. Njoku will retain his role as Chief Operating Officer, focusing on long-term growth, innovation, and global operations, while CEO Randall Lipps will concentrate on strategic collaborations. Njoku previously held executive leadership roles at Medtronic plc and other health-related companies.
Nnamdi Njoku Appointed President of Omnicell
Omnicell, Inc. has announced the appointment of Nnamdi Njoku as President, effective July 1, 2026. Njoku will continue in his role as Chief Operating Officer, while Randall Lipps remains Chief Executive Officer and Chairman of the Board. In his expanded role, Njoku will lead Omnicell's long-term growth strategy, innovation roadmap, and global operations, focusing on product, innovation, and customer experience, including the launch of Omnicell Titan XT and expansion of the OmniSphere platform.
Nnamdi Njoku appointed President of Omnicell (OMCL) while Randall Lipps remains CEO
Omnicell, Inc. has appointed Nnamdi Njoku as President, effective July 1, 2026, where he will also continue in his role as Chief Operating Officer. Randall A. Lipps will step down from the President role but will remain Chief Executive Officer and Chairman of the Board, with no changes to his compensation. Njoku will focus on Omnicell's long-term growth strategy, global operations scaling, and product innovation, including initiatives like the Omnicell Titan XT system and the OmniSphere platform.
(OMCL) Movement as an Input in Quant Signal Sets
This article provides an in-depth AI-generated analysis for Omnicell Inc. (OMCL), highlighting a positive near-term sentiment with a potential to overcome mid-term weakness within a long-term strength context. It outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
Omnicell | 4: Statement of changes in beneficial ownership of securities-Officer Manley Corey J
The document is a Statement of Changes in Beneficial Ownership of Securities (Form 4) filed by Omnicell. It reports a transaction involving Officer Manley Corey J. This filing indicates changes in his ownership of company securities.
Do Options Traders Know Something About Omnicell Stock We Don't?
Options traders are showing significant interest in Omnicell (OMCL) stock, indicated by high implied volatility for August 21, 2026 $65.00 Call options, suggesting expectations of a substantial price movement. This comes as analysts have a positive outlook on Omnicell, with two increasing earnings estimates for the current quarter and the company holding a Zacks Rank #1 (Strong Buy). The article suggests that this high implied volatility, combined with strong analyst sentiment, could present a trading opportunity for options traders.
Price to sales forward of Omnicell, Inc. – NASDAQ:OMCL
This page provides financial information for Omnicell, Inc. (NASDAQ: OMCL), specifically focusing on its forward price-to-sales ratio. The content appears to be a stub or a data placeholder from TradingView, indicating where detailed financial metrics would typically be displayed for the company.
Price to earnings forward of Omnicell, Inc. – MUN:OC9
This article provides financial information for Omnicell, Inc. (MUN:OC9), specifically its Price to Earnings Forward metric. It appears to be a stub or an incomplete data point from a financial platform like TradingView, as it lacks detailed analysis or specific values beyond the title and general market information. The content highlights the stock's listing on the Munich Stock Exchange.
Price to book forward of Omnicell, Inc. – MUN:OC9
This article provides financial data for Omnicell, Inc. (MUN:OC9), specifically focusing on its "Price to book forward" metric. The content highlights the company's financial overview on the Munich Stock Exchange, indicating it is currently market closed with no trades.
Kimberly Haught Steps into Director of Global Talent Acquisition Role at Omnicell
Kimberly Haught has been appointed Director, Global Talent Acquisition at Omnicell, where she will lead global talent strategies and strengthen partnerships to attract top talent. Her promotion follows her success as Senior Manager, Talent Acquisition at Omnicell since 2025, where she reimagined hiring practices. Haught brings extensive experience from previous leadership roles at HR Power 10, CSG, and other companies, positioning Omnicell to enhance its talent capabilities in healthcare technology.
How Investors May Respond To Omnicell (OMCL) Options Volatility Surge Signaling Anticipated Stock Swing
Options activity for Omnicell (OMCL) has surged, particularly with the Aug. 21, 2026 US$65.00 call, indicating that traders anticipate a significant stock movement. This increased implied volatility suggests a shift in sentiment rather than immediate fundamental changes, and investors should consider Omnicell's recent Q1 2026 guidance and growth forecasts. The article also encourages investors to explore beyond the options spike and delve into the company's comprehensive analysis.
Do Options Traders Know Something About Omnicell Stock We Don't?
Options traders are showing significant interest in Omnicell (OMCL) stock, indicated by high implied volatility on the August 21, 2026 $65.00 Call, suggesting expectations of a large price movement. Despite this, analysts have a "Strong Buy" rating on Omnicell and have recently increased earnings estimates, leading to speculation that this volatility could present a trading opportunity, possibly for selling premium.
How Investors May Respond To Omnicell (OMCL) Options Volatility Surge Signaling Anticipated Stock Swing
Omnicell (OMCL) recently experienced a spike in options activity, particularly with the Aug. 21, 2026 US$65.00 call, indicating that traders anticipate a significant stock movement. While this surge reflects shifting sentiment rather than immediate fundamental changes, it highlights investor expectations around the company’s future performance. Investors should consider Omnicell's Q1 2026 revenue guidance and ongoing risks like regulatory scrutiny when evaluating the potential impact of this volatility.
Do Options Traders Know Something About Omnicell Stock We Don't?
Options traders are showing significant interest in Omnicell (OMCL) stock, with high implied volatility for August 21, 2026 $65.00 Call options. This suggests expectations of a big price movement. Analysts currently rate Omnicell as a Zacks Rank #1 (Strong Buy), with two analysts increasing earnings estimates for the current quarter, which could be signaling a potential trading opportunity.
Do Options Traders Know Something About Omnicell Stock We Don't?
Options traders are showing high implied volatility for Omnicell, Inc. (OMCL) stock, particularly for the Aug. 21, 2026 $65.00 Call option, suggesting expectations of a significant price movement. Despite this, analysts have a positive outlook, with Omnicell currently holding a Zacks Rank #1 (Strong Buy) and recent upward revisions to earnings estimates. This situation could present an opportunity for options traders to sell premium, betting that the stock won't move as much as the implied volatility suggests.
Omnicell (OMCL) Stock Could Be 36.3% Undervalued After Specialty Pharmacy Leadership Hire
Omnicell (OMCL) recently appointed Dan Mandoli as Senior Vice President and General Manager of Specialty Pharmacy Services, a move expected to support its Specialty Pharmacy and 340B objectives. Despite recent market fluctuations, with a 13.82% 90-day return but a 12.07% drop over 30 days, the stock is considered 36.3% undervalued, trading at $39.05 against a fair value of $61.29. The company's transition to a cloud-native OmniSphere platform and recurring SaaS revenues is anticipated to improve margins and predictability, though potential risks like tariff costs or slower SaaS adoption could impact profitability.
Omnicell (OMCL) Stock Could Be 36.3% Undervalued After Specialty Pharmacy Leadership Hire
Omnicell (OMCL) stock is being re-evaluated after the appointment of Dan Mandoli as Senior Vice President and General Manager of Specialty Pharmacy Services, a move supporting its Specialty Pharmacy and 340B initiatives. The company is considered 36.3% undervalued by some metrics, trading at $39.05 against a fair value of $61.29, driven by expectations for its cloud-native OmniSphere platform and transition to SaaS-based revenues. However, the stock's high P/E ratio of 86.9x compared to the industry average raises valuation risk, despite the positive outlook from its DCF analysis.
Omnicell Inc (OMCL) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Omnicell Inc (OMCL)'s dividend and stock split history, noting that no dividends have been distributed in the past five years and no stock split data is available. It includes current stock information such as market capitalization and P/E ratio, and general company details.
Omnicell Inc (OMCL) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Omnicell Inc. (OMCL), highlighting its major institutional investors and their proportional holdings. It also provides a breakdown of shareholder types and historical institutional shareholding data.
Omnicell Inc (OMCL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Omnicell Inc (OMCL), segmented by business line and geographical region. As of April 6, FY2025, the company's main revenue streams are Connected devices, software licenses, and other (47.73%), Technical services (21.95%), and SaaS and Expert Services (21.87%). The vast majority of Omnicell's revenue, 89.89%, comes from the United States.
Liquidity Mapping Around (OMCL) Price Events
This article from Stock Traders Daily analyzes Omnicell Inc. (NASDAQ: OMCL), noting weak near and mid-term sentiment despite a positive long-term outlook. It identifies an exceptional 63.8:1 risk-reward setup targeting a 19.1% gain with minimal risk and provides three distinct AI-generated trading strategies. The analysis includes multi-timeframe signal assessments for various holding periods.
What Omnicell (OMCL)'s New Specialty Pharmacy Leader Means For Shareholders
Omnicell (OMCL) recently appointed Dan Mandoli as SVP and General Manager of Specialty Pharmacy Services, signaling a strategic move to scale its specialty pharmacy and 340B businesses. This hire reinforces Omnicell's focus on tech-enabled, recurring pharmacy services, a key factor in its investment narrative, though the company still faces challenges regarding revenue growth and profitability given macro pressures on hospital budgets. The article suggests this leadership change could be a catalyst for more durable earnings, with Omnicell projecting significant revenue and earnings growth by 2029.
Omnicell (OMCL) Stock Valuation Check After Mixed Recent Performance Moves
Omnicell (OMCL) has experienced mixed performance recently, with its stock roughly flat over the past day but up 10% in the last three months, despite a 12% drop in the past month. The company is currently trading at $37.83, significantly below its narrative fair value of $61.29, suggesting it might be undervalued based on its transition to recurring SaaS-based revenue and the rollout of its OmniSphere platform. However, concerns remain regarding high P/E ratios compared to the industry and potential tariff pressures or macro headwinds affecting hospital spending.
Omnicell (OMCL) Stock Valuation Check After Mixed Recent Performance Moves
Omnicell (OMCL) has experienced mixed performance recently, with its stock roughly flat over the past day but down 12% in the last month and up 10% over three months. Despite a rich P/E ratio, Simply Wall St's narrative suggests the stock is 38.3% undervalued at $37.83 against a fair value of $61.29, driven by recurring revenue from its OmniSphere platform. Investors should consider both the potential for undervaluation due to future growth and risks from tariff pressures or slower hospital spending.
This Week’s Leadership Moves: Mars Snacking, Omnicell, and TD Bank Group
CDO Magazine provides a weekly overview of significant executive appointments and leadership transitions within the global data, AI, and analytics ecosystem. This edition highlights key leadership changes at Mars Snacking, Omnicell, and TD Bank Group, among others, focusing on how these roles support digital transformation and AI strategy. The featured moves include critical positions such as Chief Information Security Officer, SVP of Data & AI, and Global Head of Data, Analytics & AI Governance & Strategy.
Earnings Preview: Omnicell to Report Financial Results Pre-market on April 28
This article announces that Omnicell (NASDAQ: OMCL) is expected to report its financial results for the first quarter of fiscal year 2026 pre-market on April 28. Analysts project the company will post earnings of $0.09 per share, a significant decline from $0.51 per share in the same period last year. Revenue is estimated to be $237.95 million.
Omnicell appoints Dan Mandoli to lead specialty pharmacy unit
Omnicell, Inc. has appointed Dan Mandoli as Senior Vice President and General Manager of Specialty Pharmacy Services, leveraging his 30 years of experience in pharmacy operations. This strategic hire is expected to drive growth in Omnicell's Specialty Pharmacy and 340B businesses, which are considered key for delivering value to health systems. The company recently reported strong Q1 2026 results and has a perfect Piotroski Score, indicating strong financial health.
Omnicell Names Dan Mandoli to Lead Specialty Pharmacy Services Business
Omnicell has appointed Dan Mandoli as senior vice president and general manager of Specialty Pharmacy Services, leveraging his 30 years of experience to expand the company's specialty pharmacy and 340B services. This strategic hire aims to enhance Omnicell's offerings for health systems navigating complex medication management and reimbursement, reinforcing the company's focus on specialty pharmacy as a key growth driver. Mandoli's background includes leadership roles at Altruix, Elevance Health, McKinsey & Company, and Express Scripts, where he focused on scaling specialty pharmacy businesses and optimizing operations.
Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business
Omnicell, Inc. has appointed Dan Mandoli as Senior Vice President and General Manager, Specialty Pharmacy Services. Mandoli, a veteran healthcare executive with over 30 years of experience, will oversee the Company's Specialty Pharmacy and 340B businesses, which are expected to be key growth drivers for Omnicell. His expertise in building and scaling specialty pharmacy operations is anticipated to enhance Omnicell's value proposition for customers and support its long-term growth strategy.
Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business
Omnicell, a healthcare technology provider, has appointed Dan Mandoli as Senior Vice President and General Manager of its Specialty Pharmacy Services business. Mandoli brings over 30 years of experience in pharmacy operations and specialty pharmacy services, having held leadership roles at Alteryx, Elevance Health, and Express Scripts. His expertise is expected to be instrumental in driving the growth and scaling of Omnicell's Specialty Pharmacy and 340B businesses, which are considered key growth drivers for the company.
Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business
Omnicell, a leading healthcare technology provider, has appointed Dan Mandoli as Senior Vice President and General Manager of Specialty Pharmacy Services. Mandoli brings over 30 years of experience in pharmacy operations and specialty pharmacy to the role. His expertise is expected to drive growth in Omnicell's Specialty Pharmacy and 340B businesses, enhancing value for health systems and improving patient outcomes.
Omnicell Shareholders Back Governance Amendment And Long Term Growth Focus
Omnicell (NasdaqGS:OMCL) shareholders have approved an amendment to the company's Certificate of Incorporation, signaling support for governance changes despite mixed recent stock performance. This amendment could influence future decisions regarding capital allocation, corporate control, and Omnicell's focus on software integration and healthcare-automation solutions. Investors will be watching closely how these changes support the company's long-term growth narrative and affect executive accountability and investor influence.
Should Omnicell’s (OMCL) Governance Moves and Conference Spotlight Recast Its Recurring Revenue Narrative?
Omnicell (OMCL) recently had shareholders approve a charter amendment and is set to present at a Goldman Sachs conference, signaling growing confidence in its medication management platform and recurring revenue strategy. These developments, alongside improved analyst earnings expectations and a Zacks Rank #1 (Strong Buy) rating, are prompting a re-evaluation of Omnicell's investment narrative. While the company projects significant revenue and earnings growth by 2029, investors are advised to consider the potential for tighter hospital capital budgets and differing analyst views on its transition to higher recurring revenue.
OMCL Technical Analysis & Stock Price Forecast
The article provides a technical analysis of Omnicell Inc (OMCL) as of June 5, 2026. It indicates a "Neutral" overall technical sentiment based on aggregating 11 technical signals, with 6 indicating buy and 5 indicating sell. Key indicators like RSI (52.068) and MACD (0.6) are discussed, along with support ($41.133) and resistance ($45.283) levels and various moving averages.
Should Omnicell’s (OMCL) Governance Moves and Conference Spotlight Recast Its Recurring Revenue Narrative?
Omnicell (OMCL) recently received shareholder approval for a charter amendment and is slated to present at a Goldman Sachs healthcare conference, alongside recent analyst upgrades and improved earnings outlooks. These developments are strengthening confidence in the company's medication management platform and recurring revenue strategy. While these events are positive, investors should still consider the potential risks from tightening hospital capital budgets.
Should Omnicell’s (OMCL) Governance Moves and Conference Spotlight Recast Its Recurring Revenue Narrative?
Omnicell (OMCL) shareholders approved a charter amendment and the company is presenting at the Goldman Sachs 47th Annual Global Healthcare Conference, signalling increased confidence in its recurring revenue strategy. Analysts have upgraded earnings expectations, leading to a "Strong Buy" rating, reflecting optimism about Omnicell's potential for predictable, higher-margin recurring revenue. However, investors should remain cautious about potential tightening of hospital capital budgets.
Why (OMCL) Price Action Is Critical for Tactical Trading
Omnicell Inc. (NASDAQ: OMCL) is exhibiting weak near-term sentiment but long-term strength, with resistance currently being tested. Stock Traders Daily's AI models have generated three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—to capitalize on these conditions, highlighting a significant short setup risk-reward ratio. The analysis provides specific entry, target, and stop-loss levels across various time horizons.
Omnicell (OMCL) may find a bottom soon, here's why you should buy the stock now
This article suggests Omnicell (OMCL) stock may be nearing its bottom and presents reasons why investors should consider buying. It likely delves into technical indicators, recent financial performance, or market conditions that could support a potential rebound for the company.
Q1 2026 Earnings Analysis: Healthcare Tech for Providers Sector Performance - News and Statistics
This article analyzes the Q1 2026 earnings for the Healthcare Technology for Providers sector, focusing on Privia Health (NASDAQ:PRVA) and Omnicell (NASDAQ:OMCL). Overall, the sector saw robust performance with revenues exceeding analyst projections by 1.1% and share prices rising an average of 6%. While Privia Health surpassed revenue forecasts but missed EPS estimates, Omnicell delivered an outstanding quarter with strong revenue growth and exceeding both EBITDA guidance and EPS estimates.
Wall Street Analysts Predict a 40.57% Upside in Omnicell (OMCL): Here's What You Should Know
Wall Street analysts predict a 40.57% upside for Omnicell (OMCL), with a mean price target of $61.29 and a low standard deviation indicating strong agreement. Despite general skepticism about price targets, Omnicell's positive earnings estimate revisions and a Zacks Rank #1 (Strong Buy) reinforce the potential for stock appreciation. Investors are advised to use price targets as a starting point for research rather than the sole basis for investment decisions.
Omnicell (OMCL) director Scott E. Bruce granted 4,627 restricted shares
Omnicell (OMCL) director Scott E. Bruce was granted 4,627 restricted shares of common stock as equity compensation for his board service. These shares, with a grant price of $0.00, will vest in full on the one-year anniversary of the grant date and increase his direct holdings to 27,600 shares. This transaction aligns the director's compensation with the company's long-term performance.
